

## CHMP2B Antibody (N-term) Blocking peptide

Synthetic peptide Catalog # BP13303a

## **Specification**

## CHMP2B Antibody (N-term) Blocking peptide - Product Information

**Primary Accession** 

**Q9UQN3** 

# CHMP2B Antibody (N-term) Blocking peptide - Additional Information

**Gene ID 25978** 

#### **Other Names**

Charged multivesicular body protein 2b, CHMP25, Chromatin-modifying protein 2b, CHMP2b, Vacuolar protein sorting-associated protein 2-2, Vps2-2, hVps2-2, CHMP2B

# **Target/Specificity**

The synthetic peptide sequence used to generate the antibody AP13303a was selected from the N-term region of CHMP2B. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

#### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

#### Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

#### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

## CHMP2B Antibody (N-term) Blocking peptide - Protein Information

# Name CHMP2B

### **Function**

Probable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis and the budding of enveloped viruses (HIV-1 and other lentiviruses). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4.



#### **Cellular Location**

Cytoplasm, cytosol. Late endosome membrane; Peripheral membrane protein

#### **Tissue Location**

Widely expressed. Expressed in brain, heart, skeletal muscle, spleen, kidney, liver, small intestine, pancreas, lung, placenta and leukocytes. In brain, it is expressed in cerebellum, cerebral cortex, medulla, spinal chord, occipital lobe, frontal lobe, temporal lobe and putamen.

## CHMP2B Antibody (N-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

### • Blocking Peptides

CHMP2B Antibody (N-term) Blocking peptide - Images

### CHMP2B Antibody (N-term) Blocking peptide - Background

This gene encodes a component of the heteromeric ESCRT-IIIcomplex (Endosomal Sorting Complex Required for Transport III) thatfunctions in the recycling or degradation of cell surfacereceptors. ESCRT-III functions in the concentration andinvagination of ubiquitinated endosomal cargos into intralumenal vesicles. The protein encoded by this gene is found as a monomer in the cytosol or as an oligomer in ESCRT-III complexes on endosomalmembranes. It is expressed in neurons of all major regions of thebrain. Mutations in this gene result in one form of familialfrontotemporal lobar degeneration.

# CHMP2B Antibody (N-term) Blocking peptide - References

Kaivorinne, A.L., et al. Eur. J. Neurol. 17(11):1393-1395(2010)Ghanim, M., et al. J. Neurol. (2010) In press: Yamazaki, Y., et al. Neurosci. Lett. 477(2):86-90(2010)Tsai, C.P., et al. Neurobiol. Aging (2010) In press: Cox, L.E., et al. PLoS ONE 5 (3), E9872 (2010):